Post by Gilead Sciences

Name: #GileadNews: The European Commission (EC) approves our treatment for first-line metastatic triple-ne
Uploaded: 2026-06-23T13:04:34.457Z
Channel: Gilead Sciences
Description: #GileadNews: The European Commission (EC) approves our treatment for first-line metastatic triple-negative breast cancer (mTNBC) for patients who are not candidates for PD-(L)1 inhibitors. Read how t

832,629 followers

#GileadNews: The European Commission (EC) approves our treatment for first-line metastatic triple-negative breast cancer (mTNBC) for patients who are not candidates for PD-(L)1 inhibitors. Read how this marks a much-needed advancement for an aggressive disease and expands treatment options for the mTNBC community: https://gilead.inc/3QEIe8W

Video Content